Hologic (HOLX) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
In recent times, investors have been increasingly drawn to companies operating in the molecular diagnostics space, a rapidly growing segment within the broader in-vitro diagnostics (IVD) market. According to Roots Analysis, the IVD market is projected to witness a 6.2% compound annual growth rate through 2035.
Hologic (HOLX) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Hologic (HOLX) concluded the recent trading session at $61.27, signifying a +0.67% move from its prior day's close.
HOLX's diagnostics strength, robust international potential and new board addition support its "Hold" case. Yet, ongoing global uncertainties remain a drag.
Hologic (HOLX) reachead $61.77 at the closing of the latest trading day, reflecting a +0.73% change compared to its last close.
Hologic (HOLX) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
In the most recent trading session, Hologic (HOLX) closed at $61.89, indicating a +0.68% shift from the previous trading day.
Hologic's Surgical business has been driving strong broad-based performance by expanding access to technologies in new global markets.
As Hologic works through the changing macroeconomic and geopolitical landscape, its long-term potential makes it a solid hold.
Hologic (HOLX) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Hologic (HOLX) reported earnings 30 days ago. What's next for the stock?